Ratings LUMIBIRD

Equities

LBIRD

FR0000038242

Market Closed - Euronext Paris 11:35:06 2024-05-31 am EDT 5-day change 1st Jan Change
12.85 EUR -.--% Intraday chart for LUMIBIRD -4.81% +5.50%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
+5.50% 308M -
+7.01% 217B
B
+11.01% 190B
B-
+19.20% 143B
B-
+30.79% 111B
A-
+1.48% 64.59B
A-
+13.95% 52.36B
B+
-0.16% 48.45B
B+
-6.20% 38.03B
A
+0.91% 35.6B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes